1. The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma.
- Author
-
Chang, Cunjie, Rajasekaran, Muthukumar, Qiao, Yiting, Dong, Heng, Wang, Yu, Xia, Hongping, Deivasigamani, Amudha, Wu, Minjie, Sekar, Karthik, Gao, Hengjun, Sun, Mengqing, Niu, Yuqin, Li, Qian, Tao, Lin, Yan, Zhen, Wang, Menglan, Chen, Shasha, Zhao, Shujuan, Chen, Dajing, and Li, Lina
- Subjects
HEPATOCELLULAR carcinoma ,ALTERNATIVE RNA splicing ,MESSENGER RNA ,LYSINE ,RNA ,GLUTAMIC acid - Abstract
Deregulation of alternative splicing is implicated as a relevant source of molecular heterogeneity in cancer. However, the targets and intrinsic mechanisms of splicing in hepatocarcinogenesis are largely unknown. Here, we report a functional impact of a Splicing Regulatory Glutamine/Lysine-Rich Protein 1 (SREK1) variant and its regulator, Serine/arginine-rich splicing factor 10 (SRSF10). HCC patients with poor prognosis express higher levels of exon 10-inclusive SREK1 (SREK1
L ). SREK1L can sustain BLOC1S5-TXNDC5 (B-T) expression, a targeted gene of nonsense-mediated mRNA decay through inhibiting exon-exon junction complex binding with B-T to exert its oncogenic role. B-T plays its competing endogenous RNA role by inhibiting miR-30c-5p and miR-30e-5p, and further promoting the expression of downstream oncogenic targets SRSF10 and TXNDC5. Interestingly, SRSF10 can act as a splicing regulator for SREK1L to promote hepatocarcinogenesis via the formation of a SRSF10-associated complex. In summary, we demonstrate a SRSF10/SREK1L /B-T signalling loop to accelerate the hepatocarcinogenesis. Alternative splicing is dysregulated in hepatocellular carcinoma. Here, the authors investigate the role of the splice variant of Splicing Regulatory Glutamic Acid and Lysine Rich Protein 1 (SREK1) and its upstream regulator, Serine/arginine-rich splicing factor 10 (SRSF10) in sustaining the oncogenic signal. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF